SUBSCRIBE
SUBSCRIBE
News   Drug Development

Gentium S.p.A.'s Stem Cell Complication Drug Fails Trial

August 19, 2009 | 
1 min read
Bookmark and Share

Reuters -- Italian biopharmaceutical firm Gentium S.p.A. said its experimental drug to treat veno-occlusive disease, a complication of stem cell transplantation, missed the main goal of a late-stage study.
Clinical research Phase III Europe
MORE ON THIS TOPIC
Cardiovascular disease
Amgen Builds Case for Repatha To Prevent Heart Disease With Late-Stage Data
October 3, 2025
 · 
1 min read
 · 
Tristan Manalac
IN PARTNERSHIP WITH PII
Hit Me With Your Best Shot: Understanding Autoinjectors and Combination Drug Delivery Systems
October 2, 2025
 · 
1 min read
 · 
BioSpace Insights
Podcast
M&A Picks Up, Walmsley Moves On, Pfizer’s MFN Deal and Hope for Huntington’s
October 1, 2025
 · 
2 min read
 · 
Heather McKenzie
Tablets. Medicinal capsules on a white background. pharmacies in the country. medicines in the state. Lots of capsules for treatment. Pharmacy network of the country.
Opinion
The Urgent Need To Redefine the Future of UK Biotech
October 1, 2025
 · 
6 min read
 · 
Kerstin Papenfuss